… , placebo or observation for extended treatment for secondary prevention of VTE. … Extended
VTE treatment was defined as management beyond the first 3 months of acute VTE treatment…

… reduce venous thromboembolism recurrence risk in patients with unprovoked VTE and a low
bleeding risk for extended treatment … the extended treatment for venous thromboembolism. …

… The need for extended venous thromboembolism (VTE) treatment beyond 3 to 6 months is
… recurrence if treatment is stopped against the risk of bleeding from continuing treatment. The …

… was the composite of symptomatic recurrent venous thromboembolism or death from any …
extended treatment for venous thromboembolic diseases. Recurrent venous thromboembolism …

… 92% decrease in the rate of recurrent venous thromboembolism as compared with placebo
in the … Current options for extended treatment after a first unprovoked venous thromboembolic …

… First, patients who required extended treatment with … with placebo for extended treatment of
venous thromboembolism, … to determine the utility of continuing treatment for longer periods. …

… The duration of long-term treatment and the decision for extended treatment vary
depending on risk of recurrent VTE. Three months is usually recommended as the shortest …

… , but edoxaban does not have specific approval for extended treatment). CrCl 30 to 50, 30
mg OD in Canada or the European Union (in the United States, same dosing as for acute VTE …

… for a simplified treatment of VTE with a lower risk of bleeding regardless of etiology or
extent of the VTE (except for massive PE) and has made extended secondary prevention more …

Traditionally, venous thromboembolism (VTE) resulting from major transient risk factors (eg, …
treatment duration; unlike VTE provoked by major transient risk factors, extended …